261 related articles for article (PubMed ID: 12465452)
1. SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis.
Wright GL
Expert Rev Mol Diagn; 2002 Nov; 2(6):549-63. PubMed ID: 12465452
[TBL] [Abstract][Full Text] [Related]
2. Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid.
Li J; Zhao J; Yu X; Lange J; Kuerer H; Krishnamurthy S; Schilling E; Khan SA; Sukumar S; Chan DW
Clin Cancer Res; 2005 Dec; 11(23):8312-20. PubMed ID: 16322290
[TBL] [Abstract][Full Text] [Related]
3. Proteome analysis for the identification of tumor-associated biomarkers in gastrointestinal cancer.
Fels LM; Buschmann T; Meuer J; Reymond MA; Lamer S; Röcken C; Ebert MP
Dig Dis; 2003; 21(4):292-8. PubMed ID: 14752218
[TBL] [Abstract][Full Text] [Related]
4. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays.
Fung ET; Yip TT; Lomas L; Wang Z; Yip C; Meng XY; Lin S; Zhang F; Zhang Z; Chan DW; Weinberger SR
Int J Cancer; 2005 Jul; 115(5):783-9. PubMed ID: 15704152
[TBL] [Abstract][Full Text] [Related]
5. Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform.
Shiwa M; Nishimura Y; Wakatabe R; Fukawa A; Arikuni H; Ota H; Kato Y; Yamori T
Biochem Biophys Res Commun; 2003 Sep; 309(1):18-25. PubMed ID: 12943657
[TBL] [Abstract][Full Text] [Related]
6. Contributions of advanced proteomics technologies to cancer diagnosis.
Ciordia S; de Los Ríos V; Albar JP
Clin Transl Oncol; 2006 Aug; 8(8):566-80. PubMed ID: 16952845
[TBL] [Abstract][Full Text] [Related]
7. A proteomic signature of ovarian cancer tumor fluid identified by highthroughput and verified by targeted proteomics.
Poersch A; Grassi ML; Carvalho VP; Lanfredi GP; Palma CS; Greene LJ; de Sousa CB; Carrara HHA; Candido Dos Reis FJ; Faça VM
J Proteomics; 2016 Aug; 145():226-236. PubMed ID: 27222041
[TBL] [Abstract][Full Text] [Related]
8. [Screening of differentially expressed proteins associated with directional highly lymphatic metastasis in ovarian carcinoma cell lines using SELDI-TOF-MS technology].
Guan X; Li DR; Wang Q; Li L; Ruan HY; Zhang W
Ai Zheng; 2008 Nov; 27(11):1155-60. PubMed ID: 19000445
[TBL] [Abstract][Full Text] [Related]
9. Integrative genomic data mining for discovery of potential blood-borne biomarkers for early diagnosis of cancer.
Yang Y; Pospisil P; Iyer LK; Adelstein SJ; Kassis AI
PLoS One; 2008; 3(11):e3661. PubMed ID: 18987750
[TBL] [Abstract][Full Text] [Related]
10. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification.
Issaq HJ; Veenstra TD; Conrads TP; Felschow D
Biochem Biophys Res Commun; 2002 Apr; 292(3):587-92. PubMed ID: 11922607
[TBL] [Abstract][Full Text] [Related]
11. Challenges of using mass spectrometry as a bladder cancer biomarker discovery platform.
Schiffer E; Mischak H; Theodorescu D; Vlahou A
World J Urol; 2008 Feb; 26(1):67-74. PubMed ID: 18175124
[TBL] [Abstract][Full Text] [Related]
12. Clinical proteomics for cancer biomarker discovery and therapeutic targeting.
Krieg RC; Paweletz CP; Liotta LA; Petricoin EF
Technol Cancer Res Treat; 2002 Aug; 1(4):263-72. PubMed ID: 12625785
[TBL] [Abstract][Full Text] [Related]
13. Proteomic approaches to biomarker discovery in prostate and bladder cancers.
Adam BL; Vlahou A; Semmes OJ; Wright GL
Proteomics; 2001 Oct; 1(10):1264-70. PubMed ID: 11721637
[TBL] [Abstract][Full Text] [Related]
14. Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers.
Verma M; Wright GL; Hanash SM; Gopal-Srivastava R; Srivastava S
Ann N Y Acad Sci; 2001 Sep; 945():103-15. PubMed ID: 11708463
[TBL] [Abstract][Full Text] [Related]
15. Plasma proteomic pattern as biomarkers for ovarian cancer.
Lin YW; Lin CY; Lai HC; Chiou JY; Chang CC; Yu MH; Chu TY
Int J Gynecol Cancer; 2006; 16 Suppl 1():139-46. PubMed ID: 16515582
[TBL] [Abstract][Full Text] [Related]
16. Tissue and serum proteomic profiling for diagnostic and prognostic bladder cancer biomarkers.
Schwamborn K; Gaisa NT; Henkel C
Expert Rev Proteomics; 2010 Dec; 7(6):897-906. PubMed ID: 21142890
[TBL] [Abstract][Full Text] [Related]
17. Contribution of oncoproteomics to cancer biomarker discovery.
Cho WC
Mol Cancer; 2007 Apr; 6():25. PubMed ID: 17407558
[TBL] [Abstract][Full Text] [Related]
18. Mass spectrometric characterization of protein structure details refines the proteome signature for invasive ductal breast carcinoma.
Röwer C; Koy C; Hecker M; Reimer T; Gerber B; Thiesen HJ; Glocker MO
J Am Soc Mass Spectrom; 2011 Mar; 22(3):440-56. PubMed ID: 21472563
[TBL] [Abstract][Full Text] [Related]
19. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery.
Celis JE; Gromov P; Cabezón T; Moreira JM; Ambartsumian N; Sandelin K; Rank F; Gromova I
Mol Cell Proteomics; 2004 Apr; 3(4):327-44. PubMed ID: 14754989
[TBL] [Abstract][Full Text] [Related]
20. Proteomics of breast carcinoma.
Somiari RI; Somiari S; Russell S; Shriver CD
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Feb; 815(1-2):215-25. PubMed ID: 15652811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
